
Dianthus Therapeutics' DNTH.O shares surge 13.2% on Tues to $36, highest since Apr 2022, adding to strong gain in previous session
DNTH shares on Mon finished up 20% after co's mid-stage trial win for its muscle-weakening drug claseprubart
After the bell Mon, co commenced $150 mln stock offering to fund preclinical and clinical development activities, and for working capital and general purposes
Jefferies, TD Cowen, Evercore and Stifel are joint bookrunners for the offering
Dianthus has ~32.19 mln shares outstanding for about $1.2 bln current market cap
Raymond James early Tues hiked its PT by $7 to $63
All 13 brokerages covering DNTH are bullish with "strongbuy" avg rating; median PT is $51.50, per LSEG data
With the move on the session, shares up ~90% over the past three months, putting them up ~65% YTD